AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Diabesity Identifies a Distinct Cardiometabolic Phenotype in Heart Failure with Preserved Ejection Fraction: Insights from the ARFey-PRESER Registry
By Moris C, Coronel ML, GARCIA BRASCA DF et al.
Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome driven by distinct pathophysiological mechanisms. The coexistence of obesity and diabetes mellitus (“diabesity”) has emerged as a potential cardiometabolic phenotype, but its clinical and prognostic implications in real-world HFpEF populations remain incompletely understood. Objective: To characterize the clinical profile, cardiac phenotype, and outcomes associated with diabesity in patients with HFpEF enrolled in the ARFey-PRESER registry. Methods: ARFey-PRESER is a prospective multicenter registry conducted by the Argentine Federation of Cardiology. Patients with HFpEF (LVEF ≥50%) and evidence of structural heart disease were included. Diabesity was defined as diabetes mellitus plus obesity (BMI ≥30 kg/m ² ). Clinical characteristics, echocardiographic findings, and outcomes were compared between patients with and without diabesity. Outcomes included heart failure hospitalization (HFH) at 12 months, all-cause mortality at 12 and 24 months, and a composite endpoint of death or HFH at 12 months. Results: Among 502 patients with complete metabolic characterization, 233 (46.4%) had diabesity. Compared with patients without diabesity, those were younger (69.3±10.1 vs 75.3±11.5 years; p<0.001) with higher rates of hypertension (95.0% vs 85.1%; p<0.001), sedentary lifestyle (71.4% vs 34.9%; p<0.001), sleep apnea (30.3% vs 2.5%; p<0.001), hypothyroidism (24.5% vs 15.3%; p=0.009), and multimorbidity (5.2±1.4 vs 2.9±1.3; p<0.001). Despite greater metabolic burden, patients with diabesity had lower prevalence of atrial fibrillation (31.5% vs 44.7%; p=0.02), smaller left atrial volume (42.6±13.7 vs 49.3±18.7 mL; p<0.001), lower pulmonary hypertension (29.7% vs 45.8%; p=0.001), lower pulmonary artery systolic pressure (34.9±13.4 vs 40.0±16.0 mmHg; p<0.001), and lower E/e′ ratio (12.9±4.8 vs 14.8±5.7; p=0.002).Clinical outcomes were significantly more favorable in the diabesity group, with lower HFH (7.7% vs 13.4%; p=0.041), lower 12-month mortality (4.3% vs 9.7%; p=0.02), lower 24-month mortality (5.6% vs 13.0%; p=0.005), and lower incidence of the composite endpoint (10.3% vs 20.1%; p=0.003). Conclusions: In this contemporary multicenter HFpEF registry, diabesity identified a highly prevalent cardiometabolic phenotype characterized by greater metabolic multimorbidity but less atrial remodeling, lower filling pressures, and reduced pulmonary hypertension. Despite a heavier burden of metabolic comorbidities, patients with diabesity experienced significantly fewer HF hospitalizations and lower mortality, supporting the concept of a distinct cardiometabolic HFpEF phenotype with unique structural and prognostic characteristics.